LMLaure Milliat-Guittard

Laure Milliat-Guittard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laure Milliat-Guittard has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    REalist COllaborative eVAluation of a work disability prevention programme for breast cancer survivors: Protocol of the RECOVA-FASTRACS realist evaluation (Preprint)

    by Apolline Blazer, Sabrina Rouat, Laure Guittard, Pauline Drouin, Julien Péron, Béatrice Fervers, Julien Carretier, Guillaume Broc, Laurent Letrilliart, Jean-Baptiste Fassier, et al.

    Background: Women with breast cancer face many barriers to returning to work (RTW) after their treatment. The Facilitating and Sustaining the Return to Work After Breast Cancer (FASTRACS) intervention aims to facilitate and sustain functional RTW. Objective: The main objective of the RECOVA-FASTRACS (Realist Collaborative Evaluation of a Work Disability Prevention Program for Breast Cancer Survivors) study is to evaluate the processes using a realist approach that analyzes what works, how, for whom, and under what circumstances. Methods: The RECOVA-FASTRACS study uses a mixed methods design to assess the implementation, context, and impact mechanisms of the FASTRACS intervention. The qualitative analysis will include 2 main components: a trajectory analysis and a focus group assessment. The trajectory analysis will examine the experiences of women who participated in the intervention and key individuals involved in their RTW process. We will use semistructured interviews according to the multiple-case study method. Additionally, to explore organizational and professional practices, focus groups will be conducted with professionals who deliver the intervention. To analyze the trajectories, embedded and iterative integration will combine the qualitative findings with relevant quantitative data from the FASTRACS randomized controlled trial for 5 domains: personal situation, professional situation, RTW, care pathway, intervention tool use, and perceived usefulness. Results: The RECOVA-FASTRACS study received funding in 2022. Recruitment and qualitative data collection began in month 6. Final analyses are expected to be completed by the end of 2026, with dissemination of the main findings anticipated in late 2027. Conclusions: Our mixed methods realist evaluation will provide a detailed analysis of the intervention processes, helping to identify impact mechanisms within specific contexts. This approach is meant to ensure a more informed and realist deployment of the intervention by professionals following the study.

  • Open Access

    REalist COllaborative eVAluation of a work disability prevention programme for breast cancer survivors: Protocol of the RECOVA-FASTRACS realist evaluation (Preprint)

    by Apolline Blazer, Sabrina Rouat, Laure Guittard, Pauline Drouin, Julien Péron, Béatrice Fervers, Julien Carretier, Guillaume Broc, Laurent Letrilliart, Jean-Baptiste Fassier, et al.

    BACKGROUND Women with breast cancer face many barriers to return to work (RTW) after their treatment. The FAcilitating and SusTain the Return to work After breast Cancer (FASTRACS) intervention aims to facilitate and sustain functional RTW. OBJECTIVE The main objective of the RECOVA-FASTRACS study is to evaluate the processes of the using a realist approach that analyses what works, how, for whom and under what circumstances. METHODS The RECOVA-FASTRACS study uses a mixed-methods design to assess the implementation, context, and impact mechanisms of the FASTRACS intervention. The qualitative analysis will include two main components: a trajectory analysis and a focus group assessment. The trajectory analysis will examine the experience of women who participated in the intervention and key individuals involved in their RTW process. We will use semi-structured interviews according to the multiple-case study method. Additionally, to explore organisational and professional practices, focus groups will be conducted with professionals who deliver the intervention. RESULTS To analyse the trajectories, embedded and iterative integration will combine the qualitative findings, with relevant quantitative data from the FASTRACS randomised controlled trial for five domains (i.e. personal situation, professional situation, return to work, care pathway, intervention tool use and perceived usefulness). CONCLUSIONS Our mixed-methods realist evaluation will provide a detailed analysis of the intervention processes, helping to identify impact mechanisms within specific contexts. This approach is meant to ensure a more informed and realist deployment of the intervention by professionals following the study. CLINICALTRIAL

  • Open Access

    Prevalence of Fabry Disease in Patients on Dialysis in France

    by Florence Sens, Laure Guittard, Bertrand Knebelmann, Olivier Moranne, Gabriel Choukroun, Valérie de Précigout, Cécile Couchoud, Isabelle Deleruyelle, Léa Lancelot, Liên Tran Thi Phuong, et al.

    Numerous prevalence studies on Fabry disease (FD, OMIM #301500) have been conducted in dialysis populations across the world with variable and controversial results. The FABRYDIAL study aimed to estimate the prevalence of FD in patients aged 18 to 74 years on chronic dialysis in France. This cross-sectional study was conducted in patients undergoing dialysis. One hundred and twenty-four dialysis centers participated. Patients with proven causes of nephropathy unrelated to FD were excluded. Alpha-galactosidase A activity was assayed in men, and both α-galactosidase A and lyso-Gb3 were assayed in women from dried blood spots. GLA gene sequencing was performed in case of abnormal values. If a variant was identified, a diagnosis validation committee was consulted for adjudication. Among the 6032 targeted patients, 3088 were included (73.6% of the eligible patients). Biochemical results were available for 2815 (1721 men and 1094 women). A genetic variant of GLA was identified in five patients: a benign c.937G>T/p.(Asp313Tyr) variant in two individuals, a likely benign c.427G>A/(p.Ala143Thr) variant, a likely benign c.416A>G/(p.Asn139Ser) variant, and a pathogenic c.1185dupG/p.Phe396Glyfs variant. Among the screened patients, the prevalence was 0.058% [0.010;0.328] in males, 0% [0.000;0.350] in females, and 0.035% [0.006;0.201] when both genders were pooled. Among all patients aged 18–74 years undergoing dialysis without a previously known cause of nephropathy unlinked to FD, the prevalence was 0.028% [0.006;0.121]. The prevalence of FD in a cohort of French dialysis patients was low. However, considering the prognostic impact of earlier diagnosis, signs of FD should be sought in patients with nephropathies of uncertain etiology.


  • Open Access

    Developing a Return to Work Intervention for Breast Cancer Survivors with the Intervention Mapping Protocol: Challenges and Opportunities of the Needs Assessment

    by Jean-Baptiste Fassier, Marion Lamort-Bouché, Guillaume Broc, Laure Guittard, Julien Péron, Sabrina Rouat, Julien Carretier, Béatrice Fervers, Laurent Letrilliart, Philippe Sarnin

    Return to work (RTW) is an important step for breast cancer survivors (BCSs). However, they face many barriers that affect particularly women with low socioeconomic status (SES). Health care, workplace, and insurance actors lack knowledge and collaborate poorly. No intervention to date has proven effective to reduce social disparities in employment after breast cancer. The intervention mapping (IM) protocol is being used in France to develop, implement, and evaluate an intervention to facilitate and sustain RTW after breast cancer [FAciliter et Soutenir le retour au TRAvail après un Cancer du Sein (FASTRACS) project]. The research question of this study was to elicit the needs for RTW after breast cancer from various stakeholders’ point of view. The aim of this study was to describe the process and the preliminary results of the needs assessment of the FASTRACS project. Different methods were followed to (a) establish and work with a planning group and (b) conduct a needs assessment to create a logic model of the problem. A planning group was organized to gather the stakeholders with the research team. A review of the literature and indicators was conducted to identify the magnitude of the problem and the factors influencing RTW. A qualitative inquiry was conducted with 12 focus groups and 48 individual semi-structured interviews to explore the needs and experience of the stakeholders. The results of these tasks were the proposition of a charter of partnership to structure the participative process, a review of the scientific evidence and indicators, and the description by the stakeholders of their needs and experience. Many stakeholders disagreed with the concept of “early intervention.” They advocated for a better support of BCSs during their RTW, emphasized as a process. Anticipation, intersectoral collaboration, and workplace accommodation were mentioned to fit the needs of the BCS and their environment. A logic model of the problem was elaborated from these data. The ability of the model to consider specific characteristics of women with low SES is discussed, with a view to developing the FASTRACS intervention through the next steps of the IM protocol.


  • Relation entre effets indésirables médicamenteux et prescription hors ou sans autorisation de mise sur le marché (AMM)

    by K. An Nguyen, Y. Mimouni, A. Lajoinie, N. Paret, C. Castellan, S. Malik, L. El-Amrani, L. Milliat-Guittard, C. Carcel, B. Kassai

  • SFRP CO-05 – Relation entre effets indésirables médicamenteux et prescription sans/hors AMM

    by K.A. Nguyen, A. Lajoinie, N. Paret, Y. Mimouni, L. Milliat-Guittard, C. Castellan, A.M. Schott, T. Vial, B. Kassai


  • SFP P-161 - Formes orales en pédiatrie: état des lieux

    by A. Lajoinie, E. Henin, A.C. Castellan, S. Malik, L. Milliat-Guittard, K.A. Nguyen, B. Kassai


  • SFP CO-48 - Préparations magistrales et hospitalières orales administrées chez l’enfant hospitalisé

    by A. Lajoinie, E. Henin, A.C. Castellan, S. Malik, L. Milliat-Guittard, K.A. Nguyen, B. Kassai


  • Influence of Donor Age on Islet Isolation and Transplantation Outcome

    by Nadja Niclauss, Domenico Bosco, Philippe Morel, Sandrine Demuylder-Mischler, Coralie Brault, Laure Milliat-Guittard, Cyrille Colin, Geraldine Parnaud, Yannick D. Muller, Laurianne Giovannoni, et al.

    It has been suggested that the age of human organ donors might influence islet isolation and transplantation outcome in a negative way due to a decrease of in vivo function in islets isolated from older donors. We retrospectively analyzed 332 islet isolations according to donor age. We determined isolation outcome by islet yields, transplantation rates, and β-cell function in vitro. Transplanted patients were divided into two groups depending on donor age (n=25 and n=31 patients for ≤45- and >45-year-old donors, respectively). We assessed islet graft function by C-peptide/glucose ratio, β score, secretory units of islets in transplantation index, and insulin independence rate at 1, 6, and 12 months after transplantation. There was no difference in islet yields between the two groups (251,900±14,100 and 244,600±8400 islet equivalent for ≤45- and >45-year-old donors, respectively). Transplantation rates and stimulation indices were similar in both groups as well. All islet graft function parameters were significantly higher at 1-month follow-up in patients who had received islets from younger donors. At 6-month follow-up after second or third injection and at 12-month follow-up, secretory units of islets in transplantation indices and C-peptide/glucose ratios were significantly higher in patients with donors aged 45 years or younger. These data suggest that, despite similar outcomes of the isolation procedure, islet graft function is significantly influenced by donor age. These results may have important consequences in the definition of pancreas allocation criteria.